Replies to post #86049 on Biotech Values

[ThomasS]

MNTA/NVS/TEVA: Teva Amends Copaxone Suit Against MNTA/NVS:
...and we know that TEVA proposes to amend the suit; we do not know if the 3 additional patents will even come into play.
Unless, of course, such amending is normally granted.

[biopearl]

Re Teva lawsuit. Recent Momenta cc implied some (however small) possibility of a summary judgement in the Dec hearings. Does this new wrinkle make that less likely? bp

[biomaven0]

>>Teva contends that any company that files an application for any glatiramoid, via an ANDA or 505(b)(2) application, should conduct pre-clinical testing as well as full-scale, placebo-controlled clinical trials with measured clinical endpoints in MS patients to establish safety, efficacy and immunogenicity in this patient population.<<

So funny to see them on the other side of the fence. Their patent attorneys must be freaking out and having to copy their normal opponents' boiler plate instead of their own.